JPS5992348A - 生体試料の分析方法 - Google Patents
生体試料の分析方法Info
- Publication number
- JPS5992348A JPS5992348A JP20337482A JP20337482A JPS5992348A JP S5992348 A JPS5992348 A JP S5992348A JP 20337482 A JP20337482 A JP 20337482A JP 20337482 A JP20337482 A JP 20337482A JP S5992348 A JPS5992348 A JP S5992348A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- peak
- column
- sample
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000007519 polyprotic acids Polymers 0.000 claims abstract description 11
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 9
- 208000019423 liver disease Diseases 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 abstract description 16
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract description 9
- 239000002253 acid Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000012856 packing Methods 0.000 abstract description 4
- 210000004556 brain Anatomy 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 235000006408 oxalic acid Nutrition 0.000 abstract description 3
- 239000004135 Bone phosphate Substances 0.000 abstract description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract description 2
- 238000007796 conventional method Methods 0.000 abstract description 2
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000000306 component Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- -1 silane compound Chemical class 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20337482A JPS5992348A (ja) | 1982-11-19 | 1982-11-19 | 生体試料の分析方法 |
| DE8383304555T DE3374604D1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| EP83304555A EP0102769B1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| CA000433955A CA1220700A (en) | 1982-08-06 | 1983-08-05 | Aqueous solution as an eluant used in liquid chromatography |
| US06/795,275 US4666861A (en) | 1982-08-06 | 1985-11-05 | Aqueous solution as an eluent used in liquid chromatography |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20337482A JPS5992348A (ja) | 1982-11-19 | 1982-11-19 | 生体試料の分析方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5992348A true JPS5992348A (ja) | 1984-05-28 |
| JPH0337710B2 JPH0337710B2 (enExample) | 1991-06-06 |
Family
ID=16472969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20337482A Granted JPS5992348A (ja) | 1982-08-06 | 1982-11-19 | 生体試料の分析方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5992348A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63205565A (ja) * | 1987-02-20 | 1988-08-25 | Toshihito Hiraoka | 肝機能検査方法 |
| CN104101679A (zh) * | 2014-07-24 | 2014-10-15 | 天津市第一中心医院 | 反相-高效液相色谱对人体血液和尿液中草酸浓度的测定方法 |
-
1982
- 1982-11-19 JP JP20337482A patent/JPS5992348A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63205565A (ja) * | 1987-02-20 | 1988-08-25 | Toshihito Hiraoka | 肝機能検査方法 |
| CN104101679A (zh) * | 2014-07-24 | 2014-10-15 | 天津市第一中心医院 | 反相-高效液相色谱对人体血液和尿液中草酸浓度的测定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0337710B2 (enExample) | 1991-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4234317A (en) | Apparatus and method for fractionation of lipoproteins | |
| JP4515786B2 (ja) | 全血中の分析対象物の計測に対するヘマトクリットの影響を減らす方法ならびに当該方法で有用な試験キット及び試験用品 | |
| Prieto et al. | Synthesis of a molecularly imprinted polymer and its application for microextraction by packed sorbent for the determination of fluoroquinolone related compounds in water | |
| US20100284996A1 (en) | Assays for Detection of Von Willebrand Factor (vWF) Multimers and for Degradation of vWF by Agents Such as Adamts13 and Related Methods | |
| EP0698793A2 (en) | A method for clinical examination based on the structures of immunoglobin G-linked oligosaccharides | |
| Simonet et al. | Determination of myo‐inositol phosphates in food samples by flow injection‐capillary zone electrophoresis | |
| Krutzen et al. | Determination of glomerular filtration rate using iohexol clearance and capillary sampling | |
| JPH08501638A (ja) | 毛管電気泳動による尿蛋白分析のための試料準備方法 | |
| Elrouf et al. | Interference of hemolysis in the estimation of plasma aspartate aminotransferase, potassium and phosphate | |
| JPS5992348A (ja) | 生体試料の分析方法 | |
| Castro-Castro et al. | The first case of chronic otitis media due to Kerstersia gyiorum in Korea | |
| CN117929585B (zh) | 分步内标法检测干血斑中的神经递质 | |
| CN116500014B (zh) | 一种基于纸色谱和表面增强拉曼散射技术在复杂基质中同时定量检测尿酸和肌酐浓度的方法 | |
| JPS5992349A (ja) | 生体試料の分析法 | |
| Warade | Comparison of glycated hempglobin with HPLC and capillary electrophoresis | |
| de la Calle Guntiñas et al. | Determination of haemoglobin A1c by liquid chromatography using a new cation-exchange column | |
| Connolly et al. | Potential sources of errors in cation-exchange chromatographic measurement of plasma taurine. | |
| CN112903846B (zh) | 一种测定利伐沙班及其杂质的分析方法 | |
| US5164090A (en) | Process for the direct chromatographic analysis of drugs and metabolites in whole blood samples using internal surface reverse phase technology | |
| Mills | Routine analysis of porphyrins in urine | |
| JP3547879B2 (ja) | フィブリノーゲン中のシアリル糖鎖による生化学検査方法およびフィブリノーゲンの精製方法 | |
| JPS5940254A (ja) | 生体試料の分析方法 | |
| JPS59196460A (ja) | 生体試料成分の分離検出法 | |
| JP3704594B2 (ja) | カテコールアミン分析方法 | |
| JPS63212861A (ja) | バニリルマンデル酸、ホモバニリン酸およびクレアチニンの同時分析方法およびその装置 |